Welcome to our dedicated page for Sesen Bio news (Ticker: sesn), a resource for investors and traders seeking the latest updates and insights on Sesen Bio stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sesen Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sesen Bio's position in the market.
Sesen Bio (Nasdaq: SESN) reported its Q3 2020 results, highlighting revenue of $11.2 million from a license agreement with Qilu Pharmaceutical. The lead program, VicineumTM, is in the follow-up stage of a Phase 3 trial for high-risk, BCG-unresponsive NMIBC. The company completed its BLA submission to the FDA and a successful Pre-Submission meeting with EMA, with potential approvals expected in early 2021 and early 2022, respectively. Cash and equivalents stand at $42.0 million, with a net loss of $22.6 million for the quarter.
Sesen Bio (SESN) will hold a conference call on November 9, 2020, at 8:00 a.m. ET to review its Q3 operating results. The call will also provide updates on the analytical comparability studies for Vicineum, which is crucial for the Biologics License Application (BLA) submission. Vicineum targets EpCAM antigens in treating high-risk non-muscle invasive bladder cancer (NMIBC) and is currently in a Phase 3 trial. The results are anticipated to support its registration for patients who are BCG-unresponsive.
Sesen Bio (Nasdaq: SESN) announced a successful pre-submission meeting with the European Medicines Agency (EMA) for Vicineum, targeting BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) in Europe. Insights from the meeting will aid the Marketing Authorization Application (MAA) validation and regulatory process. This follows EMA's confirmation of Vicineum's eligibility for MAA submission. The company aims to complete all pre-submission activities by the end of 2020. Vicineum is in a Phase 3 trial for NMIBC, addressing a significant unmet medical need.
Sesen Bio (Nasdaq:SESN) announced a partnership with Cardinal Health for exclusive 3PL and specialty pharmaceutical distribution of its lead program, Vicineum, in the U.S. Vicineum, currently in a Phase 3 trial targeting high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), utilizes a unique fusion protein approach. The collaboration with Cardinal Health, strategically located near a FedEx hub, enhances supply chain efficiency. Sesen retains worldwide rights for Vicineum, excluding Greater China, where it partners with Qilu Pharmaceutical.